Alexion Pharmaceuticals, Inc. ALXN
Set alert
182.50 +182.50 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 12.74
- Beta
- 1.26
- Short ratio
- 0.00
- Inst. own
- 88.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 29, 2021
- 50-d avg
- 182.75
- 200-d avg
- 165.77
- 1y target
- 177.36
Analyst view
Consensus: hold
Hold
Price target (mean) 177.36 -2.8% downside
Now 182.50
- Target (low)
- 166.00
- Target (mean)
- 177.36
- Target (high)
- 205.00
Ratings (0m) 21 18 buy · 3 hold · 0 sell
- Strong buy6
- Buy12
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 16
- 2 months ago 16
- 3 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 3.33 | 3.09 – 3.88 | 3.11 | +7.1% | 1.65B | +14.0% | 13 |
| Next quarter | 3.39 | 3.06 – 3.83 | 3.24 | +4.6% | 1.71B | +7.4% | 13 |
| Current year | 13.49 | 12.72 – 15.17 | 12.51 | +7.8% | 6.71B | +10.6% | 13 |
| Next year | 14.33 | 12.98 – 17.50 | 13.49 | +6.2% | 7.22B | +7.6% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 23, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Feb 5, 2021 | SVB Leerink | Maintained | — | Outperform |
| Jan 8, 2021 | Raymond James | Downgrade | Outperform | Market Perform |
| Dec 16, 2020 | Truist Securities | Downgrade | Buy | Hold |
| Dec 15, 2020 | Citigroup | Downgrade | Buy | Neutral |
| Dec 14, 2020 | Credit Suisse | Downgrade | Outperform | Neutral |
| Dec 14, 2020 | BMO Capital | Downgrade | Outperform | Market Perform |
| Dec 14, 2020 | Baird | Downgrade | Outperform | Neutral |
| Dec 14, 2020 | SVB Leerink | Maintained | — | Outperform |
| Nov 20, 2020 | Bernstein | Initiated | — | Market Perform |
| Oct 30, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Oct 30, 2020 | SVB Leerink | Maintained | — | Outperform |
| Oct 28, 2020 | UBS | Initiated | — | Neutral |
| Oct 13, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Sep 1, 2020 | Stifel | Maintained | — | Hold |
| Jul 31, 2020 | Raymond James | Maintained | — | Outperform |
| Jul 31, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jun 1, 2020 | Credit Suisse | Maintained | — | Outperform |
| May 29, 2020 | SVB Leerink | Maintained | — | Outperform |
| May 7, 2020 | BMO Capital | Maintained | — | Outperform |
| May 7, 2020 | Raymond James | Maintained | — | Outperform |
| May 7, 2020 | SVB Leerink | Maintained | — | Outperform |
| May 7, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| May 6, 2020 | CFRA | Reiterated | — | Strong Buy |
| Apr 28, 2020 | Cantor Fitzgerald | Initiated | — | Neutral |
| Apr 17, 2020 | JP Morgan | Maintained | — | Overweight |
| Apr 15, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Mar 17, 2020 | Oppenheimer | Downgrade | Outperform | Perform |
| Mar 5, 2020 | B of A Securities | Downgrade | Buy | Neutral |
| Feb 3, 2020 | Nomura | Maintained | — | Buy |